Related Experiment Video

Updated: Jun 28, 2026

RhoC GTPase Activation Assay
09:58

RhoC GTPase Activation Assay

Published on: August 22, 2010

DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway

V Ullmannova-Benson1, M Guan, X Zhou

  • 1Laboratory of Experimental Carcinogenesis, National Cancer Institute, Bethesda, MD 20892-4262, USA.

Leukemia
|October 17, 2008
PubMed

Insights

Deleted in liver cancer 1 (DLC1) is silenced in multiple myeloma (MM) via promoter hypermethylation. Reactivating DLC1 inhibits MM cell proliferation, invasion, and migration, suggesting potential epigenetic therapies for MM.

Area of Science:

  • Molecular oncology
  • Epigenetics
  • Hematological malignancies

Background:

  • Deleted in liver cancer 1 (DLC1) is a tumor suppressor gene encoding a RhoGTPase-activating protein.
  • DLC1 is frequently downregulated or silenced in various cancers due to epigenetic modifications or genomic deletion.
  • The role of DLC1 in hematological malignancies, particularly multiple myeloma (MM), remains largely unexplored.

Purpose of the Study:

  • To investigate the frequency and mechanism of DLC1 downregulation in multiple myeloma (MM).
  • To evaluate the potential of DLC1 as a diagnostic marker for MM.
  • To assess the therapeutic potential of restoring DLC1 function in MM.

Main Methods:

  • Analysis of DLC1 promoter methylation status in 44 MM cell lines.
  • Assessment of DLC1 expression levels in MM cell lines.
  • Treatment of MM cell lines with demethylating and acetylating agents.
  • Re-expression of DLC1 in MM cells using adenoviral vectors.
  • Evaluation of cell proliferation, invasion, migration, RhoA activity, and actin cytoskeleton organization.

Main Results:

  • DLC1 promoter hypermethylation was identified in 43 out of 44 MM cell lines, leading to DLC1 silencing in 41.
  • Tumor-specific methylation and DLC1 silencing were observed at a high frequency, suggesting potential as a diagnostic marker.
  • Combined epigenetic therapy reactivated DLC1 expression and suppressed MM cell proliferation.
  • Restoration of DLC1 expression inhibited MM cell invasion and migration, reduced RhoA activity, and reorganized the actin cytoskeleton.

Conclusions:

  • DLC1 promoter hypermethylation is a frequent event in multiple myeloma, leading to tumor suppressor gene silencing.
  • DLC1 re-expression exhibits significant anti-proliferative, anti-invasion, and anti-migration effects in MM cells.
  • DLC1 and the RhoA pathway represent promising targets for novel epigenetic and molecular targeted therapies for MM.

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion09:23

Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion

Published on: April 2, 2020

Related Concept Videos

Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cell Polarization by Rho Proteins01:21

Cell Polarization by Rho Proteins

Cell polarity is the asymmetric distribution of cellular and membrane components, making one side of the cell different from the other. This polarity is essential to many processes such as embryogenesis, axon migration, glucose transport across epithelial cells, and directional cell migration. A migrating cell responds to intracellular or extracellular signals via molecular cascades that reorganize the actin cytoskeleton to establish this polarity. In these cells, the Rho family proteins Cdc42,...
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However, invadopodia can...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...